Background: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor
antagonist and diuretic indicated for hypertensive patients as initial therapy and those not …

Purpose: To conduct a head to head comparison of persistency and compliance associated
with representative agents used in the pharmacologic management of hypertension …

Objective: This double-blind parallel-group randomized trial compared the efficacy and
safety of fixed combination valsartan 160 mg/hydrochlorothiazide 12.5 mg (Val 160/HCTZ …

Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment
of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the …

Hypertension, a major modifiable risk factor for cardiovascular disease and global mortality,
affects approximately 31.1% of adults worldwide. Resistant hypertension, observed in 13 …

The article presents the results of large randomized controlled clinical trials confirming the
efficacy and safety of the angiotensin II receptor blocker candesartan in the treatment of …

This article presents an algorithm for choosing the optimal drug for the treatment of arterial
hypertension, classification of arterial hypertension, describes the main group of …

Hypertension is a major risk factor for coronary heart disease, stroke, heart failure and renal
disease. The Joint National Committee on Prevention, Detection, Evaluation and Treatment …

Objective To describe the efficacy, superiority and safety profile of the first-in-class
angiotensin receptor-neprilysin inhibitor “Sacubitril/Valsartan” as compared to angiotensin …

Background In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the
primary outcome (cardiac morbidity and mortality) did not differ between valsartan and …